^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecvayli (teclistamab-cqyv)

    i
    Other names: JNJ-64007957, JNJ 64007957, JNJ64007957, JNJ 7957, Ab-957, Ab 957, Ab957, JNJ7957
    Company:
    Genmab, J&J
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    6d
    EMN37 fitfix: Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. (clinicaltrials.gov)
    P2, N=150, Recruiting, European Myeloma Network B.V. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Darzalex (daratumumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    6d
    MM0125: TALIM study, for the treatment of patients affected by persisent or recurrent Multiple Myeloma with the drug teclistamab and infusions of lymphocytes from the same patient. (2025-521827-61-00)
    P1/2, N=52, Not yet recruiting, Fondazione Gimema Franco Mandelli Onlus
    New P1/2 trial
    |
    Tecvayli (teclistamab-cqyv)
    8d
    MajesTEC-9: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=614, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Feb 2026 --> Oct 2025
    Trial primary completion date
    |
    lenalidomide • bortezomib • carfilzomib • dexamethasone • pomalidomide • Tecvayli (teclistamab-cqyv)
    8d
    TEC-CARE: Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients (clinicaltrials.gov)
    P=N/A, N=200, Active, not recruiting, Intergroupe Francophone du Myelome | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Tecvayli (teclistamab-cqyv)
    8d
    Precision-Engineered CD3 T-Cell Engagers for Solid Tumours: Conditional Activation, Microenvironment Modulation, and Clinical Translation. (PubMed, Cancers (Basel))
    Next-generation TCE platforms integrating conditional activation, cytokine payloads, and checkpoint modulation-deployed with biomarker-guided selection and TME-modulating combinations-represent a transformative therapeutic strategy. With tarlatamab's phase III survival benefit establishing clinical proof-of-concept, and pivotal trials underway for xaluritamig and next-generation agents, TCEs are positioned to become standard-of-care platform therapies in biomarker-defined solid tumours by 2028-2030.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • DLL3 (Delta Like Canonical Notch Ligand 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • STEAP1 (STEAP Family Member 1)
    |
    Blincyto (blinatumomab) • Imdelltra (tarlatamab-dlle) • Tecvayli (teclistamab-cqyv) • xaluritamig (AMG 509)
    8d
    MajesTEC-7: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=1590, Recruiting, Janssen Research & Development, LLC | N=568 --> 1590
    Enrollment change
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    13d
    TRIlogy-5: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=700, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    lenalidomide • ramantamig (JNJ-5322) • Tecvayli (teclistamab-cqyv)
    1m
    IFm2022-01: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, Nantes University Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2026 --> Apr 2028
    Enrollment closed • Trial primary completion date • Minimal residual disease
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (clinicaltrials.gov)
    P1/2, N=162, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    clonoSEQ
    |
    carfilzomib • pomalidomide • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • dexamethasone injection
    2ms
    MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, University of Arkansas | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • melphalan • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    2ms
    Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Feb 2026 --> May 2026
    Trial initiation date
    |
    Tecvayli (teclistamab-cqyv)
    2ms
    Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab. (PubMed, Blood Cancer J)
    Importantly, longer dosing intervals reduced infection rates for all-grade infections (from 6.08 infections per patient-year during weekly dosing to 2.25 infections per patient-year during bimonthly dosing) and for severe infections (from 0.81 infections per patient-year during weekly dosing to 0.1 per patient-year during bimonthly dosing). These results underline the importance of the assessment of annualized infection rates to reflect the true infectious burden in patients who were treated with BCMA-directed BsAbs.
    Journal
    |
    B2M (Beta-2-microglobulin)
    |
    Tecvayli (teclistamab-cqyv)